Sarah Nemec - 28 Jan 2026 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Role
Senior VP, Finance and PAO
Signature
/s/ William P. Quinn, Attorney-in-Fact
Issuer symbol
BOLT
Transactions as of
28 Jan 2026
Net transactions value
+$576
Form type
4
Filing time
04 Feb 2026, 16:32:00 UTC
Previous filing
16 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nemec Sarah Senior VP, Finance and PAO C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY /s/ William P. Quinn, Attorney-in-Fact 04 Feb 2026 0002023538

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLT Common Stock Purchase $576 +125 +9.7% $4.61 1,415 05 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLT Employee Stock Option (Right to Buy) Award $0 +8,000 $0.000000 8,000 28 Jan 2026 Common Stock 8,000 $6.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's Employee Stock Purchase Plan , in transactions that were exempt under Rule 16b-3(c).
F2 For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026.